The German Cancer Research Center (DKFZ) is one of Europe’s largest cancer research centers. “Research for a life without cancer" is the mission of our world-class scientists and all our team members.
We investigate how cancer develops, identify cancer risk factors and search for new cancer prevention strategies. We develop new methods with which tumors can be diagnosed more precisely and cancer patients can be treated more successfully. Every contribution counts – whether in research, administration or infrastructure. This is what makes our daily work so meaningful and exciting.
For the Clinical Cooperation Unit (CCU) "Applied Tumor Immunity", we are seeking for the next possible date a
Reference number: 2026-0062
The immune system influences the efficacy of many therapies and interventions. Thus, the identification of crucial immunological parameters, such as novel biomarkers, is of great importance. The aim of the Clinical Cooperation Unit (CCU) "Applied Tumor Immunity" is the characterization of immune responses directed against the tumor and the transfer of these findings into clinical applications. A particular focus of our research is the analysis of immunological interactions between tumor cells and host or immune cells in the tumor microenvironment and periphery to identify predictive biomarkers and develop novel immunotherapeutic approaches for solid tumors (e.g., TCR T cells, CAR T cells, bispecific antibodies, and peptide vaccines).
Translational Research in Immuno-oncology and Microbiome (TRIM) is an additional research group within the CCU "Applied Tumor Immunity". Our TRIM research team investigates how the gut microbiota influences the efficacy of cancer immunotherapies. We collaborate closely with clinical and research partners at the NCT and UKHD. We apply and continuously develop state-of-the-art analytical approaches to dissect microbiota–host–tumor interactions. These include multiparametric immune profiling (flow cytometry/FACS, bead-based cytokine assays) and molecular biology techniques such as qPCR and bulk and single-cell sequencing. Our work supports the testing and development of drugs targeting novel immunological pathways. The overarching goal of our research is to elucidate mechanisms underlying patient response and resistance to immunotherapy, with a particular focus on gut microbiota–driven immunosuppression.
This is a translational research laboratory in which the candidate would be responsible for performing various lab duties. The successful candidate will assist the investigators in:
Interested candidates should submit a CV, cover letter, certificates, and contact details of two references via the online application portal.
Contact:
Yuk Ching Chan
Phone: +49 6221 56-36127
The position is initially limited to 2 years with the possibility of prolongation.
Application Deadline: 22.04.2026
Applications by e-mail cannot be accepted.
Please also note that we cannot return applications submitted by post.
Then become part of the DKFZ and join us in contributing to a life without cancer!
Apply nowWe are convinced that an innovative research and working environment thrives on the diversity of its employees. Therefore, we welcome applications from talented people, regardless of gender, cultural background, nationality, ethnicity, sexual identity, physical ability, religion and age. People with severe disabilities are given preference if they have the same aptitude.
Notice: We are subject to the regulations of the Infection Protection Act (IfSG). Therefore, all our employees must provide proof of immunity against measles.
Share this job!
Deutsches Krebsforschungszentrum | Im Neuenheimer Feld 280 | 69120 Heidelberg | www.dkfz.de